Neurocrine Biosciences saw the highest growth of 274% in patent filings and 399% in grants in December in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 116% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Neurocrine Biosciences‘s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

Neurocrine Biosciences has been focused on protecting inventions in Israel(IL) with seven publications in Q4 2023

The Israel(IL) Patent Office dominates the patent filings and grants with nearly 23% filings and 29% grants. The Israel(IL), South Korea(KR), Brazil(BR), and Australia(AU) patent Office are among the top ten patent offices where Neurocrine Biosciences is filings its patents. Among the top granted patent authorities, Neurocrine Biosciences has 43% of its grants in European Patent Office(EPO), 29% in Israel(IL) and 14% in South Korea(KR).

In terms of grant share, Neurocrine Biosciences stands in fourth position among its competitors. and secured the top positions according to recent patent publication data.

For comprehensive analysis of Neurocrine Biosciences's filings and grants, buy the databook here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.